Author:
Santini Daniele,Martini Federico,Fratto Maria Elisabetta,Galluzzo Sara,Vincenzi Bruno,Agrati Chiara,Turchi Federica,Piacentini Paola,Rocci Laura,Manavalan John S.,Tonini Giuseppe,Poccia Fabrizio
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference32 articles.
1. Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745–751
2. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA (1989) Antiresorptive dose–response relationship across three generations of bisphosphonates. Drugs Exp Clin Res 15:389–396
3. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA et al (2004) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 22:1351
4. Saad F, Gleason D, Murray R et al (2003) Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. J Urol 169(suppl):394
5. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621
Cited by
89 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献